Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $75.00 Consensus Target Price from Brokerages

Keros Therapeutics, Inc. (NASDAQ:KROS) has received an average recommendation of “Moderate Buy” from the fourteen research firms that are covering the company, MarketBeat reports. Five investment analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $52.56.

Several equities analysts have recently weighed in on the stock. Piper Sandler lowered their price objective on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a research note on Friday. Wedbush downgraded shares of Keros Therapeutics from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $47.00 to $15.00 in a research report on Friday. BTIG Research downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. William Blair cut Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Finally, Jefferies Financial Group began coverage on Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating for the company.

Keros Therapeutics Trading Up 3.2 %

Shares of KROS opened at $10.86 on Friday. The firm has a fifty day simple moving average of $36.37 and a two-hundred day simple moving average of $47.13. The firm has a market cap of $439.94 million, a PE ratio of -2.08 and a beta of 1.43. Keros Therapeutics has a 1-year low of $9.77 and a 1-year high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The firm had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business’s revenue was up 4750.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.33) EPS. As a group, research analysts forecast that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Hedge Funds Weigh In On Keros Therapeutics

A number of hedge funds have recently made changes to their positions in the business. KBC Group NV raised its stake in Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after buying an additional 280 shares during the last quarter. Values First Advisors Inc. purchased a new position in shares of Keros Therapeutics in the third quarter worth $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Keros Therapeutics in the second quarter worth $128,000. Finally, LMR Partners LLP bought a new position in shares of Keros Therapeutics during the third quarter worth $213,000. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.